Comparison of three techniques for percutaneous balloon aortic valvuloplasty of aortic stenosis in adults

[Holter monitoring during sudden arrhythmic death]

Recordings of patients wearing a Holter monitor at the time of sudden cardiac death reveal that 16-20% of these patients die due to bradyarrhythmias. Tachyarrhythmic death is found in 80-84% of these patients. In about 40% lethal ventricular fibrillation is preceded by monomorphic ventricular tachyrcardias. in 20% by polymorphic ventricular tachycardias and torsades de pointes, respectively. Primary ventricular fibrillation is rare (3-5%). Typical "warning" arrhythmias, such as ventricular pairs or nonsustained ventricular tachycardias were found only inconsistently in the hours before death, as well as elevated heart rate. Thus it seems impossible at this time, to identify reliably those patients by telemetric ECG monitoring, who are at risk of imminent sudden arrhythmic death.

The treatment of aortic stenosis: is valvuloplasty ever an alternative to surgery?

The desire to extend the principle of balloon angioplasty to cardiac valve disease is understandable and commendable. Aortic valvuloplasty is associated, however, with an excessive complication rate, as reported by the Mansfield Scientific Aortic Valvuloplasty Registry (20.5% overall, including a 4.9% death rate within 24 hours and an additional 2.6% rate within 7 days for a 7.5% 1-week mortality). In contrast, the operative mortality for aortic valve replacement now ranges from 3%-5%, with perioperative complications far less than the one in five associated with valvuloplasty. Even if the two procedures had equivalent morbidity and mortality rates, the high incidence of restenosis (30%-60% range at 6 months) for the balloon technique precludes its widespread use for aortic stenosis. Despite the poor mid- and long-term results for balloon valvuloplasty, the procedure may have limited application in some clinical situations. Indeed, there are patients with concomitant systemic illnesses or advanced age ( greater than 80 years) who would not be good surgical candidates. In particular, valvular balloon dilation may be useful in bridging a seriously ill patient to a condition more favorable for replacement therapy. With few exceptions, however, valve replacement remains the gold standard for treatment of adult aortic stenosis.

Balloon valvuloplasty for congenital aortic valve stenosis in an infant and children

Percutaneous balloon aortic valvuloplasty (BAV) was performed in 14 patients, including one critically ill infant with congenital valvular aortic stenosis (AS). BAV was effective in 13 patients (except the infant). The peak systolic pressure gradient between the left ventricle (LV) and the ascending aorta decreased from 76.6 +/- 21.6 to 29.5 +/- 15.3 mmHg (P less than 0.001). Follow-up cardiac catheterization was performed for eight patients between 1 and 3 years (1.6 +/- 1.1 years) after BAV. Restenosis was found in only one patient, and the efficacy of BAV continued significantly. Aortic regurgitation developed or increased in severity in 5 of 13 children immediately after BAV. Any other severe complication was not observed. Dilatation by BAV was not sufficient for the infant with critical AS, and acute myocardial infarction (AMI) in the lateral wall of the LV occurred during the BAV procedure. The infant died 3 days after the procedure due to AMI. It was concluded that the retrograde double balloon technique was superior to the retrograde single balloon technique. In two cases, the single balloon technique was ineffective because it was impossible to fix the balloon at the aortic annulus. However, the double balloon technique was effective in every patient. BAV is effective for AS in children, and an optional repeat trial may enable BAV to be the first choice for AS. Although BAV may be effective for neonates and infants with critical AS as an emergency treatment, much attention must be paid during the procedure.

Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results in 674 patients from the NHLBI Balloon Valvuloplasty Registry

BACKGROUND

Percutaneous balloon aortic valvuloplasty has been used as a therapeutic option for relief of valvular stenosis. This study describes patients undergoing initial percutaneous aortic balloon valvuloplasty enrolled in the National Heart, Lung, and Blood Institute (NHLBI) Balloon Valvuloplasty Registry.

METHODS AND RESULTS

Extensive baseline procedural and postprocedural data were tabulated in 674 patients during a 24-month period. Functional status was captured using standard methods and an overall functional scoring system. Complications were defined and divided into procedural, acute (within 24 hours), in-hospital, and within 30 days of the procedure. The patient population was elderly and symptomatic, with 83% greater than 70 years of age. New York Heart Association functional class (FC) III or IV congestive heart failure (CHF) was present in 76%, syncope or presyncope was present in 34%, and Canadian Heart Association class III or IV angina was present in 23%. Using an overall functional scoring system (0-100), 54% exhibited scores less than 50. Comorbid disease was common. Forty-five percent possessed at least one serious noncardiac disability as a reason for valvuloplasty. Eighty percent of those seen by a cardiothoracic surgeon were believed inappropriate for aortic valve replacement. Hemodynamically, the aortic valve area increased from 0.5 +/- 0.2 cm2 to 0.8 +/- 0.3 cm2 (p less than 0.0001), accompanied by a fall in mean and peak aortic valve gradient from 55 +/- 21 and 65 +/- 28 mm Hg to 29 +/- 13 and 31 +/- 18 mm Hg, respectively (both p less than 0.0001). Small but significant increases were observed in cardiac output, heart rate, and mean aortic pressure with minor declines in the pulmonary artery (PA) systolic and left ventricular (LV) end-diastolic pressure. One hundred sixty-seven (25%) experienced at least one significant complication within 24 hours, and 211 (31%) experienced a significant complication before discharge. Complications before hospital discharge included the need for transfusion (23%), vascular surgery (7%), cerebrovascular accident (3%), other systemic embolus (2%), myocardial infarction (2%), acute tubular necrosis (1%), or cardiac surgery (1%). Seventeen (3%) patients died during the procedure; 16 of those were due to cardiac causes. By hospital discharge, there was an additional 52 total deaths; 37 were due to cardiovascular causes. Between hospital discharge and 30 days, 23 additional deaths occurred; 18 were due to cardiac disease. At 30 days, therefore, there was a grand total of 92 (14%) deaths; 71 (11%) were due to cardiovascular-related causes. Univariate and logistic regression analysis of mortality revealed that death was most frequent in patients suffering multiorgan failure and poor LV systolic function. Thirty-day mortality was associated with a predefined high-risk subset of hypotension and NYHA class IV CHF (risk ratio, 4.4), blood urea nitrogen (BUN) greater than 30 mg/dl (risk ratio, 3.7), use of an antiarrhythmic (risk ratio, 2.9), and cardiac output less than 3.0 l/min (risk ratio, 2.4). Of the survivors (86%) at 30 days, symptomatic improvement was generally present. Seventy-five percent experienced at least one functional class improvement in CHF, and 53% experienced at least a quartile improvement in overall functional status score.

CONCLUSIONS

These data reveal that percutaneous aortic balloon valvuloplasty in an elderly and debilitated population can be done with low mortality but substantial morbidity. Mortality is greatest in patients with multiorgan failure resulting from poor cardiac output. In patients with reasonably preserved LV function who are otherwise inappropriate surgical candidates because of comorbid factors, survival and early improvement in symptomatic status are frequently observed after percutaneous aortic valvuloplasty.

Follow-up recatheterization after balloon aortic valvuloplasty. Mansfield Scientific Aortic Valvuloplasty Registry Investigators

The results of recatheterization were assessed in a select group of 95 patients enrolled in the Mansfield Scientific Aortic Valvuloplasty Registry to determine whether any procedural or patient-related variables at baseline predicted either initial immediate or follow-up (6.2 +/- 3.3 months) results. At the follow-up catheterization, 39 (41%) of the patients were in improved condition and 56 patients (59%) had recurrence of symptoms, allowing for analysis of the effect of the procedure in two symptomatic patient subsets. In the total group the aortic valve area increased initially from 0.56 +/- 0.16 to 0.87 +/- 0.27 cm2 but partial return to the baseline valve area was evident at follow-up (0.63 +/- 0.25 cm2). Similarly, the mean aortic gradient initially decreased from 72 +/- 30 to 35 +/- 16 mm Hg but then increased to 55 +/- 25 mm Hg at follow-up. Neither the initial nor the late hemodynamic results appeared affected by any definable procedural variable at the time of valvuloplasty, including the maximal diameter of balloons, number of balloons simultaneously used, mean inflation time or total number of inflations. Such technical concerns also did not seem to affect short- or long-term outcome. Similarly, no baseline hemodynamic variable clearly separated those who became increasingly symptomatic from those whose condition was improved at the 6 month interval. At recatheterization, a reduction in the aortic valve area toward baseline was observed in 24 (62%) of the 39 improved patients and in 45 (80%) of the 56 who were symptomatic.(ABSTRACT TRUNCATED AT 250 WORDS)

Aortic valvoplasty: comparison of the techniques and results of transeptal and retrograde methods

Balloon aortic valvoplasty is used in some patients with aortic valve stenosis who are unsuitable for aortic valve replacement. Complications associated with the retrograde approach can be avoided using an antegrade approach which has been less widely described. Experience of these two methods is reported and aspects of the differences in technique are emphasized. Aortic valvoplasty was attempted in 21 patients with severe aortic valve stenosis (mean gradient 65 mmHg). A significant reduction in gradient was achieved in 20 (mean reduction 59% transeptal group [four patients], 50% retrograde group [16 patients]) with symptomatic improvement in 18 patients which was maintained at follow-up (mean interval of 5.2 months, range 1-17 months) in 8/15 patients. There were only two significant, resolvable early complications and increases in aortic regurgitation were not seen. There were six late deaths but three patients improved sufficiently to undergo successful aortic valve replacement. Aortic valvoplasty provides good palliation of symptoms. In patients who are unsuitable for the retrograde approach the antegrade, transeptal approach is a satisfactory and effective alternative.